Protara Therapeutics Inc Ordinary Shares TARA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.20
- Day Range
- $4.08–4.37
- 52-Week Range
- $2.97–7.82
- Bid/Ask
- $4.10 / $4.32
- Shares Outstanding
- 56.20M
- Market Cap
- $242.80M
- Volume/Avg
- 1M / 748,818
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 51
- Website
- https://www.protaratx.com
Valuation
|
Metric
|
TARA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.30 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TARA
|
|---|---|
Quick Ratio | 15.39 |
Current Ratio | 15.69 |
Interest Coverage | — |
Quick Ratio
TARA
Profitability
|
Metric
|
TARA
|
|---|---|
Return on Assets (Normalized) | −33.82% |
Return on Equity (Normalized) | −36.26% |
Return on Invested Capital (Normalized) | −39.37% |
Return on Assets
TARA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|PB@l%V | LOCK|V@Yb | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|j$C%HpH | LOCK|R>#fS | $70B | |||
| argenx SE ADR
ARGX
| LOCK|!c%&rd? | LOCK|d# | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&tGjZY | LOCK|!H@> | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|VN^PL$ | LOCK|$&> | $36B | |||
| Moderna Inc
MRNA
| LOCK|v<tHn> | LOCK|rq | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^d?@XZf< | LOCK|SbqJ | $25B | |||
| Incyte Corp
INCY
| LOCK|BL>lQ? | LOCK|Rs | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|>sr$X% | LOCK|r@ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|!flzP% | LOCK|@X^ | $17B |
United States